Epigenetic roles of MLL oncoproteins are dependent on NF-κB.

[1]  L. Liotta,et al.  AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells , 2013, Leukemia.

[2]  F. Meng,et al.  Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways. , 2012, Cancer letters.

[3]  A. Guo,et al.  MLL1, a H3K4 methyltransferase, regulates the TNF&agr;-stimulated activation of genes downstream of NF-&kgr;B , 2012, Journal of Cell Science.

[4]  Ruiying Zhao,et al.  Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. , 2012, Cell stem cell.

[5]  Crispin J. Miller,et al.  The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. , 2012, Cancer cell.

[6]  M. Kurokawa,et al.  AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors. , 2011, Blood.

[7]  J. Hess,et al.  CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. , 2011, Cancer cell.

[8]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[9]  T. Graeber,et al.  An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. , 2011, Genes & development.

[10]  Lars Bullinger,et al.  MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.

[11]  S. Mi,et al.  MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. , 2011, Blood.

[12]  Q. Zhan,et al.  PLK1 Is Transcriptionally Activated by NF-κB during Cell Detachment and Enhances Anoikis Resistance through Inhibiting β-Catenin Degradation in Esophageal Squamous Cell Carcinoma , 2011, Clinical Cancer Research.

[13]  P. Dent,et al.  Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF‐κB and Bim , 2011, British journal of haematology.

[14]  Di Chen,et al.  Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. , 2011, Current cancer drug targets.

[15]  Stuart H. Orkin,et al.  A Myc Network Accounts for Similarities between Embryonic Stem and Cancer Cell Transcription Programs , 2010, Cell.

[16]  Kevin S. Smith,et al.  GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. , 2010, Cancer cell.

[17]  M. Caligiuri,et al.  Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. , 2010, Cancer cell.

[18]  F. Khuri,et al.  Proteasome Inhibitor PS-341 (Bortezomib) Induces Calpain-dependent IκBα Degradation* , 2010, The Journal of Biological Chemistry.

[19]  M. Cleary,et al.  A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. , 2010, Cancer cell.

[20]  Hui Zhang,et al.  MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. , 2010, Cancer cell.

[21]  A. Shilatifard,et al.  AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. , 2010, Molecular cell.

[22]  Fabien Campagne,et al.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.

[23]  K. Anderson,et al.  Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. , 2009, Blood.

[24]  Howard Y. Chang,et al.  Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. , 2009, Cell stem cell.

[25]  Ming-Ming Zhou,et al.  Brd4 Coactivates Transcriptional Activation of NF-κB via Specific Binding to Acetylated RelA , 2008, Molecular and Cellular Biology.

[26]  T. Volkert,et al.  Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. , 2008, Genes & development.

[27]  Xiaobo Xia,et al.  H3K79 methylation profiles define murine and human MLL-AF4 leukemias. , 2008, Cancer cell.

[28]  Mark J. Murphy,et al.  Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy , 2008, Nature.

[29]  Akihiko Yokoyama,et al.  Menin critically links MLL proteins with LEDGF on cancer-associated target genes. , 2008, Cancer cell.

[30]  Baolin Wu,et al.  Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. , 2008, Cancer cell.

[31]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[32]  Steven B. Bradfute,et al.  Hematopoietic fingerprints: an expression database of stem cells and their progeny. , 2007, Cell stem cell.

[33]  M. Cleary,et al.  Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. , 2007, Genes & development.

[34]  M. Cleary,et al.  Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. , 2006, Cancer cell.

[35]  Wenzheng Zhang,et al.  Dot1a-AF9 Complex Mediates Histone H3 Lys-79 Hypermethylation and Repression of ENaCα in an Aldosterone-sensitive Manner* , 2006, Journal of Biological Chemistry.

[36]  Hiroshi Handa,et al.  P-TEFb-mediated phosphorylation of hSpt5 C-terminal repeats is critical for processive transcription elongation. , 2006, Molecular cell.

[37]  J. Hess,et al.  c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. , 2005, Blood.

[38]  J. Mesirov,et al.  From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .

[39]  Matthew Meyerson,et al.  The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis , 2005, Cell.

[40]  S. Armstrong,et al.  Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. , 2005, Blood.

[41]  J. Brady,et al.  The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. , 2005, Molecular cell.

[42]  J. Licht,et al.  Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6. , 2005, Leukemia research.

[43]  Thomas Werner,et al.  MatInspector and beyond: promoter analysis based on transcription factor binding sites , 2005, Bioinform..

[44]  Yi Zhang,et al.  hDOT1L Links Histone Methylation to Leukemogenesis , 2005, Cell.

[45]  W. Herr,et al.  Leukemia Proto-Oncoprotein MLL Forms a SET1-Like Histone Methyltransferase Complex with Menin To Regulate Hox Gene Expression , 2004, Molecular and Cellular Biology.

[46]  K. Yeh,et al.  Suppression of MEK/ERK Signaling Pathway Enhances Cisplatin-induced NF-κB Activation by Protein Phosphatase 4-mediated NF-κB p65 Thr Dephosphorylation* , 2004, Journal of Biological Chemistry.

[47]  B. Peterlin,et al.  Dynamics of Human Immunodeficiency Virus Transcription: P-TEFb Phosphorylates RD and Dissociates Negative Effectors from the Transactivation Response Element , 2004, Molecular and Cellular Biology.

[48]  Peter O. Krutzik,et al.  Intracellular phospho‐protein staining techniques for flow cytometry: Monitoring single cell signaling events , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[49]  Misao Ohki,et al.  Identification of a gene expression signature associated with pediatric AML prognosis. , 2003, Blood.

[50]  D. Howard,et al.  Preferential induction of apoptosis for primary human leukemic stem cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. Howard,et al.  Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. , 2001, Blood.

[52]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[53]  T. Skov,et al.  CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. , 1999, Cancer research.

[54]  G. Stark,et al.  IRAK-M Is a Novel Member of the Pelle/Interleukin-1 Receptor-associated Kinase (IRAK) Family* , 1999, The Journal of Biological Chemistry.

[55]  K. Davies,et al.  The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. , 2007, Human molecular genetics.

[56]  E. Vellenga,et al.  Constitutive NF-κB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway , 2004, Leukemia.

[57]  M. Karin,et al.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. , 2000, Annual review of immunology.